The Biden-Harris administration's Inflation Reduction Act has enabled Medicare to negotiate with pharmaceutical companies, resulting in significant discounts on ten popular drugs, potentially saving Medicare $6 billion and reducing seniors' out-of-pocket expenses by $1.5 billion. However, critics argue that the administration is using taxpayer funds to mask substantial upcoming increases in Medicare premiums, with projections indicating premiums may triple by 2025. To mitigate voter backlash, the Centers for Medicare and Medicaid Services (CMS) have introduced a three-year subsidy program, which some Republicans claim lacks legal standing and serves political purposes. Additionally, the administration faces criticism for allegedly diverting resources from small business programs to climate initiatives. These actions have led to accusations of using federal funds for political gain and have sparked calls for investigations into the administration's policies.